The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatment
Open accessAbstract
BACKGROUND: The survival of older patients with acute myeloid leukemia has not improved. Few clinical trials have been available for older patients who are not considered fit for an intensive chemotherapy approach. METHODS: Between December 1998 and November 2003, as part of National Cancer Research Institute Acute Myeloid Leukemia 14 Trial, 217 patients, who were deemed unfit for intensive chemotherapy were randomized to receive low‐dose cytarabine (Ara‐C) (20 mg twice daily for 10 days) or hydroxyurea with or without all‐trans retinoic acid (ATRA). RESULTS: Low‐dose ara‐C produced a better remission rate (18% vs 1%; odds ratio [OR], 0.15; 95% confidence interval [95% CI], 0.06–0.37; P = .00006) and better overall survival (OR, 0.60; 95% CI, 0.44–0.81; P = .0009), which was accounted for by the achievement of complete remission (CR) (duration of CR: 80 weeks vs 10 weeks for patients with no CR). Patients who had adverse cytogenetics did not benefit. ATRA had no effect. Toxicity scores or supportive care requirements did not differ between the treatment arms. CONCLUSIONS: Older, less fit patients have a poor outcome, and few trials have been conducted in this patient group. Low‐dose ara‐C treatment was superior to best supportive care and hydroxyurea because it had greater success in achieving CR, and it could represent standard care against which new treatments may be compared in this patient group. [See editorial on pages 000–000, this issue.] Cancer 2007 © 2007 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“After decades of studies, the efficacy of ATRA to treat other acute myeloid leukaemia (AML) subtypes and solid tumours remains poor.”
From Unlocking the potential of retinoic acid in anticancer therapy (2014) · cites this paper as Burnett et al, 2007
In the citing paper
“However, other phase 2 studies showed no or non-significant effects (Milligan et al, 2006; Burnett et al, 2007).”
From Unlocking the potential of retinoic acid in anticancer therapy (2014) · cites this paper as Burnett et al, 2007
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Campos, L., Rouault, J., Sabido, O., Oriol, P., Roubi, N., Vasselon, C., Archimbaud, E., Magaud, J., & Guyotat, D. (1993) · Blood · doi:10.1182/blood.v81.11.3091.3091 · Cited by 783
Kantarjian, H. M., O'Brien, S. M., Cortes, J. E., Giles, F. J., Faderl, S. H., Jabbour, E. J., Garcia‐Manero, G., Wierda, W. G., Pierce, S. A., Shan, J., et al. (2006) · Cancer · doi:10.1002/cncr.21723 · Cited by 608
Löwenberg, B., Zittoun, R., Kerkhofs, H., Jehn, U., Abels, J., Debusscher, L., Cauchie, C., Peetermans, M. E., Solbu, G., & Suciu, S. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.9.1268 · Cited by 383
The Outcomes and Costs of Acute Myeloid Leukemia Among the Elderly
Menzin, J., Lang, K., Earle, C. C., Kerney, D. L., & Mallick, R. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.14.1597 · Cited by 276
Tilly, H., Castaigné, S., Bordessoule, D., Casassus, P., Prisé, P. Y. L., Tertian, G., Desablens, B., Henry-Amar, M., & Degos, L. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.2.272 · Cited by 259
Cheson, B. D., Jasperse, D. M., Simon, R. M., & Friedman, M. A. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.12.1857 · Cited by 210
Housset, M., Daniel, M., & Degos, L. (1982) · British Journal of Haematology · doi:10.1111/j.1365-2141.1982.tb07297.x · Cited by 189
Response of Preleukemic Syndromes to Continuous Infusion of Low-Dose Cytarabine
Wisch, J. S., Griffin, J. D., & Kufe, D. W. (1983) · New England Journal of Medicine · doi:10.1056/nejm198312293092602 · Cited by 179
Andreeff, M., Jiang, S., Zhang, X., Konopleva, M. Y., Estrov, Z. E., Snell, V., Xie, Z., Okcu, M., Sanchez‐Williams, G., Dong, J., et al. (1999) · Leukemia · doi:10.1038/sj.leu.2401573 · Cited by 153
Sexual functioning morbidity among cancer survivors. Current status and future research directions
Andersen, B. L. (1985) · Cancer · doi:10.1002/1097-0142(19850415)55:8 · Cited by 147
Flagged first, then by citations
1 of the 26 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 601–619 of 619
Tsai, D. E., Luger, S. M., Andreadis, C. B., Vogl, D. T., Kemner, A. L., Potuzak, M., Goradia, A., Loren, A. W., Perl, A. E., Schuster, S. J., et al. (2023) · doi:10.1158/1078-0432.c.6517141.v1
Venetoclax-based lower-intensity regimens for acute myeloid leukemia
Richard‐Carpentier, G. (2023) · Canadian Hematology Today · doi:10.58931/cht.2023.2125
Evaluating the Economic Burden of Acute Myeloid Leukemia in Canada
Lachaîne, J., Beauchemin, C., Dodat, F., Au, Y., Evans, W. K., Leber, B. F., Paulson, K., Schuh, A. C., & Storring, J. M. (2024) · Acta Haematologica · doi:10.1159/000537725
Kretschmer, L., Bücklein, V., Subklewe, M., & Röllig, C. (2024) · Trillium Krebsmedizin · doi:10.47184/tk.2024.06.2
Denutrition status prevails over a standard AML risk assessment in older adults
Simon, L., Caulier, A., Berthon, C., Boyer, T., Harrivel, V., Joris, M., Leduc, I., Duployez, N., Preudhomme, C., Marolleau, J., et al. (2025) · Current Research in Translational Medicine · doi:10.1016/j.retram.2025.103500
Yang, Q., Torres‐Martín, M., Taguchi, M., Brogi, A., Casalin, I., Ceneri, E., Halene, S., Dezern, A. E., Griffiths, E. A., Follo, M. Y., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.23.650336
Mayer, K. T., Birk, L., Schwab, K., Schmidt‐Wolf, I. G. H., von Lilienfeld‐Toal, M., Brossart, P., Glasmacher, A. G., & Hahn‐Ast, C. (2025) · Acta Haematologica · doi:10.1159/000545792
IV. Advances in Treatment of Acute Myeloid Leukemia in the Elderly
Hosono, N. (2024) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.113.1241
Liu, J., Huang, X.-M., Li, X.-S., Zhu, Y.-Y., Lv, P., Yang, Y., Tian, T., & Sun, W.-J. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1736302
Dalle, I. A., Yassine, A., Awada, A., Chakhachiro, Z. I., Mahfouz, R. A., Moukalled, N. M., Cheikh, J. E., & Bazarbachi, A. A. (2026) · Current Research in Translational Medicine · doi:10.1016/j.retram.2026.103576
Role of the SUMO pathway in Acute Myeloid Leukemias response to treatments
Baik, H. (2017) · theses.fr (ABES) · doi:10.70675/156a7d66zb325z4965zbd18z8c101e88ebc2
Uyemura, B. S., Hollnagel, F., Hall, A. C., Brunner, M., Gahvari, Z. J., Mattison, R. J., Liu, H., Fallon, M. J., & Nadiminti, K. V. G. (2026) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2026.2711591
Treatment of Acute Myeloid Leukemia in the Elderly
Vadnagara, H., Dua, A., Garg, S., Juneja, P., Singh, A., & Jain, A. G. (2026) · Hematology Reports · doi:10.3390/hematolrep18050070
Даваасамбуу, Б., Gritsayev, S. V., Tv, G., Тиранова, С. А., Александровна, П. Н., Martynkevtch, I. S., & Чечеткин, А. В. (2014) · Clinical oncohematology · doi:10.21320/2500-2139-2014-7-2-213-219
Metadata
- Authors
- Burnett, A. K., Milligan, D., Prentice, A. G., Goldstone, A. H., McMullin, M. F., Hills, R. K., & Wheatley, K.
- Affiliations
- Cardiff University (GB)
- Heartlands Hospital (GB)
- Derriford Hospital (GB)
- University College Hospital (GB)
- Belfast City Hospital (GB)
- Cancer Research UK Clinical Trials Unit (GB)
- Corresponding author
- Burnett, Alan K.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2007-02-21
- Volume
- 109
- Issue
- 6
- Pages
- 1114-1124
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2068556430
- Cited by
- 619
- References
- 26
- Citations by year
- 2026: 5 · 2025: 14 · 2024: 13 · 2023: 23 · 2022: 28 · 2021: 43 · 2020: 45 · 2019: 40 · 2018: 29 · 2017: 37 · 2016: 36 · 2015: 54 · 2014: 48 · 2013: 42 · 2012: 36
- FWCI
- 18.95
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer (publishedVersion)
- PubMed (publishedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Keywords
- acute myeloid leukemia, high-risk myelodysplastic syndrome, low-dose cytarabine, hydroxyurea, all-trans retinoic acid, elderly patients, complete remission, overall survival, adverse cytogenetics, best supportive care
- MeSH terms
- Acute Disease, Aged, Antineoplastic Combined Chemotherapy Protocols, Cytarabine, Female, Humans, Hydroxyurea, Leukemia, Myeloid, Male, Middle Aged, Myelodysplastic Syndromes, Risk, Survival, Tretinoin, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
